Comparison of the MLV integration profile in these tumors with Brd4 binding sites (data taken from ENCODE ID GSM1262345, murine AML MLL-AF9/NrasG12D cells) indicates that MLV IN TP-16 integrations at Brd4 sites was decreased by approximately 20% compared to MLV WT6 (Fig 4B). The gene discussed is CDKN2A; the disease is acute myeloid leukemia.